Abstract
Gene therapy is a promising approach for the treatment of a variety of disorders including genetic diseases and cancer. Among the viral vectors used in gene therapy, the lentiviral vector, based on HIV-1, is the only integrative vector able to transduce nondividing cells. The first generation of lentiviral vector was established in 1996. Since then, other generations of lentiviral vector packaging systems were developed to improve this first vector. In this chapter, we describe these different packaging systems, the generation of lentiviral vector from productive cells, the 293T cell line, and the transduction of myogenic cells with a lentiviral vector as well.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267
Taganov KD, Cuesta I, Daniel R, Cirillo LA, Katz RA, Zaret KS, Skalka AM (2004) Integrase-specific enhancement and suppression of retroviral DNA integration by compacted chromatin structure in vitro. J Virol 78:5848–5855
Scherdin U, Rhodes K, Breindl M (1990) Transcriptionally active genome regions are preferred targets for retrovirus integration. J Virol 64:907–912
Luciw PA (1996) Human immunodeficiency viruses and their replication, in Fields Virology (Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., Melnick, J. L., Monath, T. P., Roizman, B., and Straus, S. E.) 3rd ed., pp 1881–1952, Lippincott-Raven Publishers, Philadelphia, PA
Chan DC, Kim, PS (1998) HIV entry and its inhibition. Cell 93:681–684
Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR (1989) The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338:254–257
Cullen BR (1986) Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 46:973–982
Trono D (1995) HIV accessory proteins: leading roles for the supporting cast. Cell 82:189–192
Klimatcheva E, Rosenblatt JD, Planelles V (1999) Lentiviral vectors and gene therapy. Front Biosci 4:D481–496
Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173–185
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871–875
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463–8471
Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873–9880
Zufferey R, Donello JE, Trono D, Hope TJ (1999) Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73:2886–2892
Cronin J, Zhang XY, Reiser J (2005) Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5:387–398
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Pichavant, C., Tremblay, J.P. (2012). Generation of Lentiviral Vectors for Use in Skeletal Muscle Research. In: DiMario, J. (eds) Myogenesis. Methods in Molecular Biology, vol 798. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-343-1_16
Download citation
DOI: https://doi.org/10.1007/978-1-61779-343-1_16
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-342-4
Online ISBN: 978-1-61779-343-1
eBook Packages: Springer Protocols